Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Dermatology

Differential Diagnosis & Understanding Your Pathology Report

At a Glance

Scleromyxedema is diagnosed by combining widespread waxy papules and skin hardening with biopsy findings of dermal mucin, fibroblast proliferation, and fibrosis, plus testing for a monoclonal blood protein. Doctors also compare these findings with similar skin disorders.

Confirming a diagnosis of scleromyxedema is a multi-step process that involves matching what is seen on your skin with what is found under a microscope and in your blood. Because this condition is so rare, doctors use a specific set of guidelines—often called the Rongioletti criteria—to ensure an accurate diagnosis [1][2].

The Four Diagnostic Pillars

In a classic case, your doctor will look for four specific features to confirm you have scleromyxedema:

  1. Generalized Skin Eruption: A widespread appearance of small, waxy bumps (papules) and a general hardening of the skin (sclerodermoid changes) [1].
  2. Specific Biopsy Findings: A skin sample that shows a unique “triad” of changes (see the checklist below) [3].
  3. Monoclonal Gammopathy: The presence of an abnormal protein in your blood, most commonly an IgG lambda type [4][5].
  4. Absence of Thyroid Disease: Historically, doctors required patients to have a normal thyroid to be diagnosed with this condition, because severe thyroid disease can cause a different kind of mucin buildup [1]. However, modern research shows that some patients can have both thyroid issues and scleromyxedema. Exceptions require careful interpretation by a specialist to distinguish between the two [6][7].

Pathology Report Completeness Checklist

When you look at your skin biopsy report, you may see several key terms. If they are missing, do not assume the diagnosis is wrong; pathologists use different terminologies. Instead, ask your dermatologist or have a dermatopathologist (a specialist in skin pathology) review it to ensure these concepts are present:

  • Dermal Mucin: An accumulation of a jelly-like substance (glycosaminoglycans) in the middle layer of your skin. Doctors often use special stains like Colloidal Iron or Alcian Blue to make this visible [8][9].
  • Fibroblast Proliferation: An unusually high number of fibroblasts, the cells that create the skin’s structural support [8].
  • Fibrosis or Sclerosis: Evidence of scarring or hardening of the connective tissue [8].
  • Interstitial CD68-Positive Cells: Some variants of scleromyxedema look like another condition called “granuloma annulare.” Seeing these specific immune cells (histiocytes) can help the pathologist identify this “granulomatous” pattern [10][8].

Distinguishing Scleromyxedema from “Look-Alikes”

Because many conditions cause skin thickening, your doctor must carefully evaluate clues to rule out other possibilities:

Condition Diagnostic Clues
Systemic Sclerosis (Scleroderma) Usually involves Raynaud’s phenomenon (fingers turning white/blue in the cold) and specific blood antibodies (like anti-Scl-70). It also shows distinct changes in the tiny blood vessels of the fingernails. Lacking these clues makes systemic sclerosis less likely, though it is not an absolute rule [11][12].
Scleredema This also involves mucin, but the skin thickening is usually much deeper and lacks the hundreds of small, waxy bumps [13][14].
Localized Lichen Myxedematosus This is a usually localized version. It typically only appears in a few small areas and generally does not involve an abnormal blood protein or systemic progression [15][16].

The Role of Blood and Urine Tests

To evaluate the “monoclonal gammopathy” part of the diagnosis, you will likely undergo several tests:

  • SPEP and UPEP: Serum and Urine Protein Electrophoresis. these tests scan your blood and urine for “bands” of abnormal protein [17].
  • Immunofixation (IFE): This identifies exactly which type of protein is present (e.g., IgG, IgA, or IgM) and which “light chain” it uses (Kappa or Lambda) [17][18].
  • Free Light Chain (FLC) Assay: A highly sensitive blood test that measures the levels of the “puzzle pieces” of your antibodies [19].

While about 90% of patients have these proteins at diagnosis, they can sometimes appear later in the disease course. If your initial tests are negative but your skin symptoms continue, your doctor may repeat these tests in the future [4][6].

Common questions in this guide

What should a scleromyxedema skin biopsy show?
The classic biopsy pattern includes dermal mucin, increased fibroblasts, and fibrosis or sclerosis in the skin. Some cases have a granuloma-annulare-like pattern with interstitial CD68-positive cells, so a dermatopathologist may need to interpret the terminology in context.
Which blood tests help confirm scleromyxedema?
Doctors may use serum and urine protein electrophoresis, immunofixation, and a free light chain assay to detect and identify an abnormal monoclonal protein. An IgG lambda protein is common, but the exact result must be interpreted with the skin findings and other tests.
Can I have scleromyxedema if I also have thyroid disease?
Yes, some people can have both thyroid disease and scleromyxedema. Although a normal thyroid was historically part of the diagnostic rule, a specialist must now distinguish thyroid-related mucin changes from the biopsy and blood findings of scleromyxedema.
How do doctors tell scleromyxedema apart from systemic sclerosis?
Systemic sclerosis is more likely when there is Raynaud's phenomenon, disease-associated antibodies such as anti-Scl-70, and characteristic small-vessel changes around the fingernails. The absence of these findings makes systemic sclerosis less likely but does not rule it out, so doctors also consider the skin biopsy and other clinical findings.
Does an IgG lambda protein mean I have a blood cancer?
An IgG lambda result indicates an abnormal monoclonal protein, but it does not by itself determine whether the finding is MGUS or a more advanced blood disorder. A hematologist can review the result and order any additional evaluation needed.
What if my initial protein tests are normal?
A negative initial blood or urine test does not always exclude scleromyxedema because the abnormal protein can appear later. If skin symptoms continue, your doctor may repeat protein studies during follow-up.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Scleromyxedema.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my skin biopsy show the full 'classic triad' of dermal mucin, fibroblast proliferation, and fibrosis, or a more unusual granuloma-annulare-like pattern?
  2. 2.My report mentions CD68-positive cells; can you explain how this helps confirm the diagnosis over other similar conditions?
  3. 3.We found an IgG lambda paraprotein—should we consult a hematologist to determine if this is MGUS or something more advanced?
  4. 4.Since I have thyroid issues, how does that affect the interpretation of the 'absence of thyroid disease' diagnostic rule in my case?
  5. 5.How did you rule out systemic sclerosis—was it based on my lack of Raynaud's phenomenon or specific antibody tests?

References

References (19)
  1. 1

    Scleromyxedema.

    Hoffmann JHO, Enk AH

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2020; (18(12)):1449-1467 doi:10.1111/ddg.14319.

    PMID: 33373143
  2. 2

    Case for diagnosis. Lichen myxedematosus.

    Rebellato PR, Carbonar MB, Tabuti NI, Rastelli GJ

    Anais brasileiros de dermatologia 2016; (91(6)):842-843 doi:10.1590/abd1806-4841.20165725.

    PMID: 28099617
  3. 3

    [Scleromyxedema].

    Sunderkötter C, Bruns T, Pfeiffer C

    Dermatologie (Heidelberg, Germany) 2024; (75(3)):225-231 doi:10.1007/s00105-024-05303-0.

    PMID: 38363313
  4. 4

    Treatment of scleromyxedema Arndt-Gottron with a novel intravenous immunoglobulin preparation.

    Negele N, Winkler JK, Enk AH

    Dermatology reports 2026; doi:10.4081/dr.2026.10557.

    PMID: 41978975
  5. 5

    Scleromyxedema: clinical diagnosis and autopsy findings.

    Sala AC, Cunha PR, Pinto CA, et al.

    Anais brasileiros de dermatologia 2016; (91(5 suppl 1)):48-50 doi:10.1590/abd1806-4841.20164527.

    PMID: 28300892
  6. 6

    Discrete Papular Lichen Myxedematosus and Scleromyxedema with Hypothyroidism: A Report of Two Cases.

    Shenoy A, Steixner J, Beltrani V, Gottlieb A

    Case reports in dermatology 2019; (11(1)):64-70 doi:10.1159/000498881.

    PMID: 31011315
  7. 7

    Scleromyxedema in a patient with thyroid disease: an atypical case or a case for revised criteria?

    Hazan E, Griffin TD, Jabbour SA, Keller MS

    Cutis 2020; (105(1)):E6-E10.

    PMID: 32074156
  8. 8

    Histopathologic characteristics of scleromyxedema: A study of a series of 34 cases.

    Rongioletti F, Merlo G, Carli C, et al.

    Journal of the American Academy of Dermatology 2016; (74(6)):1194-200.

    PMID: 26897387
  9. 9

    Identifying the potential origin of mucin in primary cutaneous mucinoses-A retrospective study and analysis using histopathology and multiplex fluorescence staining.

    Steinmann S, Guillet C, Cheng PF, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2023; (37(7)):1302-1310 doi:10.1111/jdv.18992.

    PMID: 36807595
  10. 10

    Histopathologic Spectrum of Scleromyxedema: Classic and Granulomatous Patterns With Emphasis on Eosinophilic Infiltrates and Eccrine Gland Proliferation as Diagnostic Masqueraders.

    Caputo V, Stabile G, Guida S, et al.

    The American Journal of dermatopathology 2026; (48(7)):493-499 doi:10.1097/DAD.0000000000003211.

    PMID: 42307595
  11. 11

    Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

    Ferreli C, Gasparini G, Parodi A, et al.

    Clinical reviews in allergy & immunology 2017; (53(3)):306-336 doi:10.1007/s12016-017-8625-4.

    PMID: 28712039
  12. 12

    [Mimetics of systemic sclerosis].

    Jendrek ST, Kahle B, Riemekasten G

    Zeitschrift fur Rheumatologie 2019; (78(1)):14-23 doi:10.1007/s00393-018-0538-y.

    PMID: 30255410
  13. 13

    Sclerodermalike syndromes: Great imitators.

    Varjú C, Kumánovics G, Czirják L, et al.

    Clinics in dermatology 2020; (38(2)):235-249 doi:10.1016/j.clindermatol.2019.10.010.

    PMID: 32513403
  14. 14

    European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis.

    Knobler R, Moinzadeh P, Hunzelmann N, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2017; (31(10)):1581-1594 doi:10.1111/jdv.14466.

    PMID: 28786499
  15. 15

    Papular mucinosis, or localized lichen myxedematosis (LM) (discrete papular type).

    Christman MP, Sukhdeo K, Kim RH, et al.

    Dermatology online journal 2017; (23(12)).

    PMID: 29447654
  16. 16

    Localized Lichen Myxedematosus With Plasma Cell Light Chain Restriction: Is It the Exception or the Rule?

    Elwyn LB, Combs A, Villada G, et al.

    The American Journal of dermatopathology 2019; (41(7)):505-510 doi:10.1097/DAD.0000000000001335.

    PMID: 30601206
  17. 17

    Characterization of circulating myeloma tumor cells by next generation flowcytometry in scleromyxedema patient: a case report.

    Taha RY, Hasan S, Ibrahim F, et al.

    Medicine 2020; (99(27)):e20726 doi:10.1097/MD.0000000000020726.

    PMID: 32629647
  18. 18

    Scleromyxedema (Arndt - Gottron Syndrome) Developing Under Tenofovir Treatment for Hepatitis B: Unique Presentation in a Bulgarian Patient!

    Temelkova I, Patterson JW, Tchernev G

    Open access Macedonian journal of medical sciences 2019; (7(5)):782-785 doi:10.3889/oamjms.2019.181.

    PMID: 30962839
  19. 19

    Cutaneous diseases caused by monoclonal immunoglobulin and/or free light chains (monoclonal gammopathy of cutaneous significance).

    Adam Z, Řehák Z, Krejčí M, et al.

    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2026; (39(1)):10-30 doi:10.48095/ccko202610.

    PMID: 42172113

This page is for informational purposes only and does not replace professional medical advice. Your dermatologist, dermatopathologist, or hematologist should interpret your biopsy and blood tests in context.